Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
about
Efficacy of baricitinib in the treatment of rheumatoid arthritis.Safety profile of biological therapies for treating rheumatoid arthritis.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production.The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy.Tofacitinib: A Review in Rheumatoid Arthritis.European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.Studies with herpes zoster vaccines in immune compromised patients.Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.Chemical JAK inhibitors for the treatment of rheumatoid arthritis.Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges.
P2860
Q38652849-275C501A-8566-4EAB-9229-CA538E3046B1Q38665700-B944864D-2847-4C93-8407-C79192831438Q38751230-DB84D617-AC9B-4FB8-8DD4-819A246BE84FQ38857308-20D76044-14F6-408C-B3E8-65600FB5E6E6Q40068342-D581B236-90EB-43F1-8184-0D85AF5A1A43Q40132474-F17C89E0-6652-4B71-A2AF-A1890A89E18AQ40175407-3B332D1C-D006-44D8-850A-3433380D16A5Q43280727-3A91C285-121F-4399-9CB2-4A8B905FE397Q47338654-EE8459B1-6EF4-4C97-A235-F51EB7949B80Q47605669-E7F4A612-8F96-4122-BC66-53F958160304Q52642347-9B38E0C5-76A9-4605-A552-66C3AA7F70BDQ53791793-AD094251-6F18-4197-9DCC-F0BCD3810B4FQ54172510-93E17A1C-80F4-4699-BE46-39643552E399Q54508929-5BBD472E-7830-4272-B516-4895C87469D4
P2860
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Real-world comparative risks o ...... ents with rheumatoid arthritis
@en
Real-world comparative risks o ...... nts with rheumatoid arthritis.
@nl
type
label
Real-world comparative risks o ...... ents with rheumatoid arthritis
@en
Real-world comparative risks o ...... nts with rheumatoid arthritis.
@nl
prefLabel
Real-world comparative risks o ...... ents with rheumatoid arthritis
@en
Real-world comparative risks o ...... nts with rheumatoid arthritis.
@nl
P2093
P2860
P1476
Real-world comparative risks o ...... ents with rheumatoid arthritis
@en
P2093
Fenglong Xie
Huifeng Yun
Jeffrey R Curtis
Kevin L Winthrop
Sasha Bernatsky
P2860
P304
P356
10.1136/ANNRHEUMDIS-2016-209131
P407
P577
2016-04-25T00:00:00Z